Literature DB >> 7525852

Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function.

W Held1, G A Waanders, H Acha-Orbea, H R MacDonald.   

Abstract

Mouse mammary tumor virus (MMTV) encodes a superantigen (SAg) that promotes stable infection and virus transmission. Upon subcutaneous MMTV injection, infected B cells present SAg to SAg-reactive T cells leading to a strong local immune response in the draining lymph node (LN) that peaks after 6 d. We have used the reverse transcriptase inhibitor 3'-azido-3'-deoxythymidine (AZT) to dissect in more detail the mechanism of SAg-dependent enhancement of MMTV infection in this system. Our data show that no detectable B or T cell response to SAg occurs in AZT pretreated mice. However, if AZT treatment is delayed 1-2 d after MMTV injection, a normal SAg-dependent local immune response is observed on day 6. Quantitation of viral DNA in draining LN of these infected mice indicates that a 4,000-fold increase in the absolute numbers of infected cells occurs between days 2 and 6 despite the presence of AZT. Furthermore MMTV DNA was found preferentially in surface IgG+ B cells of infected mice and was not detectable in SAg-reactive T cells. Collectively our data suggest that MMTV infection occurs preferentially in B cells without SAg involvement and is completed 1-2 d after virus challenge. Subsequent amplification of MMTV infection between days 2 and 6 requires SAg expression and occurs in the absence of any further requirement for reverse transcription. We therefore conclude that clonal expansion of infected B cells via cognate interaction with SAg-reactive T cells is the predominant mechanism for increasing the level of MMTV infection. Since infected B cells display a memory (surface IgG+) phenotype, both clonal expansion and possibly longevity of the virus carrier cells may contribute to stable MMTV infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525852      PMCID: PMC2191775          DOI: 10.1084/jem.180.6.2347

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  24 in total

1.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection.

Authors:  D G Miller; M A Adam; A D Miller
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

2.  Synthesis of the precursor to avian RNA tumor virus internal structural proteins early after infection.

Authors:  B M Gallis; R N Eisenman; H Diggelmann
Journal:  Virology       Date:  1976-10-15       Impact factor: 3.616

3.  Two monoclonal rat antibodies with specificity for the beta-chain variable region V beta 6 of the murine T-cell receptor.

Authors:  J Payne; B T Huber; N A Cannon; R Schneider; M W Schilham; H Acha-Orbea; H R MacDonald; H Hengartner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

4.  Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent.

Authors:  G M Springett; R C Moen; S Anderson; R M Blaese; W F Anderson
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

5.  BALB.D2-Mlsa--a new congenic mouse strain.

Authors:  H Festenstein; L Berumen
Journal:  Transplantation       Date:  1984-03       Impact factor: 4.939

6.  Protein-coding potential of mouse mammary tumor virus genome RNA as examined by in vitro translation.

Authors:  C Dickson; G Peters
Journal:  J Virol       Date:  1981-01       Impact factor: 5.103

7.  Suppression of HIV infection in AZT-treated SCID-hu mice.

Authors:  J M McCune; R Namikawa; C C Shih; L Rabin; H Kaneshima
Journal:  Science       Date:  1990-02-02       Impact factor: 47.728

8.  Expression of IgD by murine lymphocytes. Loss of surface IgD indicates maturation of memory B cells.

Authors:  S J Black; W van der Loo; M R Loken; L A Herzenberg
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

9.  Positive selection determines T cell receptor V beta 14 gene usage by CD8+ T cells.

Authors:  N S Liao; J Maltzman; D H Raulet
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

10.  B cells are essential for murine mammary tumor virus transmission, but not for presentation of endogenous superantigens.

Authors:  U Beutner; E Kraus; D Kitamura; K Rajewsky; B T Huber
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  21 in total

1.  Both T and B cells shed infectious mouse mammary tumor virus.

Authors:  J L Dzuris; T V Golovkina; S R Ross
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Retrovirus-induced target cell activation in the early phases of infection: the mouse mammary tumor virus model.

Authors:  C Ardavin; F Luthi; M Andersson; L Scarpellino; P Martin; H Diggelmann; H Acha-Orbea
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  A highly sensitive in vitro infection assay to explore early stages of mouse mammary tumor virus infection.

Authors:  S Vacheron; T Renno; H Acha-Orbea
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis.

Authors:  Ellina Lytvyak; Ishwar Hosamani; Aldo J Montano-Loza; Lynora Saxinger; Andrew L Mason
Journal:  Can Liver J       Date:  2019-01-09

Review 5.  Combination antiretroviral studies for patients with primary biliary cirrhosis.

Authors:  Ellina Lytvyak; Aldo J Montano-Loza; Andrew L Mason
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

6.  In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen.

Authors:  C Krummenacher; H Diggelmann; H Acha-Orbea
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

7.  Preferential binding of mouse mammary tumor virus to B lymphocytes.

Authors:  F Baribaud; A V Shaw; L Scarpellino; H Diggelmann; H Acha-Orbea
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

8.  Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle.

Authors:  M Mpandi; L A Otten; C Lavanchy; H Acha-Orbea; D Finke
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 9.  Genetic background and environment contribute synergistically to the onset of autoimmune diseases.

Authors:  P Luppi; M R Rossiello; S Faas; M Trucco
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

10.  Evidence that the murine AIDS defective virus does not encode a superantigen.

Authors:  L Doyon; C Simard; R P Sékaly; P Jolicoeur
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.